Healthcare · Biotechnology
Price
$14.01
Market Cap
$10.9B
Employees
159
Beta
-1.31
Avg Volume
5,157,431
CEO
Robert W. Duggan
Business Description
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Business History
Price History (1 Year)
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
Stock Price / EPS (Diluted)
—
Stock Price: $14.01
EPS (Diluted): N/A
EPS (Diluted): N/A
EPS not available in income statement
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
26.74
Stock Price: $14.01
Total Equity: N/A
Shares: N/A
Total Equity: N/A
Shares: N/A
Equity not available in balance sheet
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-10.25
Market Cap: $10.87B
Total Debt: $0.00
Cash: $0.00
EBITDA: N/A
Total Debt: $0.00
Cash: $0.00
EBITDA: N/A
EBITDA not available
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$12.9B
Market Cap: $10.87B
Total Debt: $0.00
Cash: $0.00
Total Debt: $0.00
Cash: $0.00
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $14.01
Revenue: N/A
Shares: N/A
Revenue: N/A
Shares: N/A
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: N/A
Revenue: N/A
Revenue: N/A
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: N/A
Revenue: N/A
Revenue: N/A
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: N/A
Revenue: N/A
Revenue: N/A
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-340.6%
Net Income: N/A
Total Equity: N/A
Total Equity: N/A
Equity not in balance sheet
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-248.1%
Operating Income: N/A
Tax Rate: N/A
Equity: N/A
Total Debt: $0.00
Cash: $0.00
Tax Rate: N/A
Equity: N/A
Total Debt: $0.00
Cash: $0.00
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
9.87
Current Assets: N/A
Current Liabilities: N/A
Current Liabilities: N/A
Debt/Equity (Leverage — debt vs equity)
Total Debt / Total Equity
—
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: N/A
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: N/A
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: N/A
Shares: N/A
Shares: N/A
Missing from API: Revenue, Shares
Book Value/Share (Net assets per share)
(Total Assets - Total Liabilities) / Shares
—
Total Equity: N/A
Shares: N/A
Shares: N/A
Missing from API: Total Equity, Shares
FCF/Share (Real cash generated per share)
(Operating Cash Flow + CapEx) / Shares
—
Operating CF: N/A
CapEx: $0.00
Shares: N/A
CapEx: $0.00
Shares: N/A
Missing from API: Operating CF, Shares
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $14.01
Stock Price: $14.01
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: N/A
Net Income: N/A
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares SMMT against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement
Requires paid FMP plan for this ticker
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 12:53am (9h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$76.1M $64.0M – $88.3M
|
$731.7M $600.5M – $863.0M
|
$2.0B $1.6B – $2.3B
|
$3.9B $3.2B – $4.6B
|
| EBITDA |
$15.2M $12.8M – $17.7M
|
$146.3M $120.1M – $172.6M
|
$395.7M $324.7M – $466.7M
|
$785.1M $644.3M – $925.9M
|
| Net Income |
-$898.7M -$996.5M – -$738.9M
|
-$438.3M -$742.1M – $207.1M
|
$243.3M $186.5M – $300.0M
|
$1.3B $984.1M – $1.6B
|
| EPS | — | — | — | — |
Insider Trading (Recent)
Last updated: Jun 27, 2026 9:05am (1h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Zanganeh Mahkam | P-Purchase | 3,810,000.00 | $13.12 | $50.0M |
| 2026-06-12 | DUGGAN ROBERT W | P-Purchase | 3,810,000.00 | $13.12 | $50.0M |
| 2026-06-04 | DUGGAN ROBERT W | P-Purchase | 100,000.00 | $14.60 | $1.5M |
| 2026-06-04 | Zanganeh Mahkam | P-Purchase | 100,000.00 | $14.60 | $1.5M |
| 2026-06-04 | Soni Manmeet Singh | P-Purchase | 25,000.00 | $14.43 | $360,750 |
| 2026-06-04 | Soni Manmeet Singh | P-Purchase | 25,000.00 | $14.46 | $361,500 |
| 2026-01-08 | Anand Bhaskar | A-Award | 30,000.00 | $18.83 | $564,900 |
| 2026-01-02 | Zanganeh Mahkam | A-Award | 11,232.00 | $17.52 | $196,785 |
| 2026-01-02 | DUGGAN ROBERT W | A-Award | 11,232.00 | $17.52 | $196,785 |
| 2026-01-02 | Booth Robert F. | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Booth Robert F. | A-Award | 7,180.00 | $17.52 | $125,794 |
| 2026-01-02 | Xia Yu | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Huber Jeff | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Huber Jeff | A-Award | 9,885.00 | $17.52 | $173,185 |
| 2026-01-02 | Ronaghi Mostafa | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Clark Kenneth A | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Clark Kenneth A | A-Award | 17,796.00 | $17.52 | $311,786 |
| 2026-01-02 | Cesano Alessandra | A-Award | 35,000.00 | $17.52 | $613,200 |
| 2026-01-02 | Cesano Alessandra | A-Award | 3,219.00 | $17.52 | $56,397 |
| 2025-10-21 | Xia Yu | P-Purchase | 533,617.00 | $18.74 | $10.0M |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for SMMT — it's generated by the pipeline (
market-narrative step).
No community reviews yet for SMMT.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30